The hemophilia treatment center nurse’s communication challenge
The hemophilia treatment center nurse works at the intersection of a molecular diagnosis, a lifelong treatment regimen, and a family system that has inherited something it did not choose. Hemophilia A — an X-linked recessive deficiency of factor VIII, affecting approximately 1 in 5,000 male births — is one of the best-understood inherited diseases in medicine, yet the communication challenges it generates are among the most consistent the HTC nurse will face. Three of them recur across every patient panel.
The first is the paradox of prophylaxis: giving medication to someone who is not bleeding. To families outside the hemophilia world, treatment is for when there is a problem. Factor VIII concentrate infused three times per week into a child who has no visible bleed, no swollen joint, no obvious pain — this looks like overtreating a manageable condition. The HTC nurse must explain the biology of hemarthrosis before it happens: why trough factor levels below 1 percent cause spontaneous joint bleeds with normal activity, and why each bleed — even a mild one that resolves without dramatic symptoms — deposits iron into the synovial tissue and activates the inflammatory cascade that eventually produces hemophilic arthropathy, the joint destruction that defined hemophilia outcomes before the prophylaxis era.
The second is the crisis of inhibitor development: the moment a medication that worked reliably for years stops working entirely. Factor VIII inhibitors — high-affinity neutralizing antibodies produced by the patient’s immune system against infused FVIII — are the most serious complication of hemophilia A treatment. When they develop, standard factor VIII replacement is rendered useless. Understanding why — what these antibodies are, how they block FVIII function, and how bypassing agents generate a clot through a pathway that does not require FVIII at all — is essential for the family to trust a new treatment they have never heard of.
The third is the biology of X-linked inheritance and lyonization: why a female who “only carries” the hemophilia gene may have her own bleeding phenotype. The simplification that carriers are unaffected is taught in high school biology and repeated by some clinicians. The reality is that random X-chromosome inactivation produces a spectrum of factor VIII levels in obligate carriers — and those with FVIII below 50 percent bleed.
Three conversations from the hemophilia treatment center:
Scenario 1: Marco Delgado-Pérez — 34, construction foreman from Dallas, Texas
Marco Delgado-Pérez had been diagnosed with severe hemophilia A at three months old, when his mother had brought him to the pediatrician after prolonged bleeding from a heel-stick blood draw. The F8 gene sequencing had confirmed a null mutation — an intron 22 inversion, the most common severe hemophilia A mutation, producing no functional FVIII protein. He had been on prophylactic recombinant factor VIII concentrate since the age of two: three infusions per week, every Monday, Wednesday, and Friday, using a subcutaneous port placed when he was four because peripheral venous access had been too difficult for twice-weekly clinic visits.
Marco was now 34. He had graduated from high school, completed a construction management degree at a community college in Irving, and spent the last eight years as a foreman on commercial construction projects in the Dallas-Fort Worth area. He had two target joints — his left ankle and his right elbow, both of which had developed hemophilic synovitis from bleeds before his prophylaxis regimen was fully optimized in his teens — but his joint function was otherwise well-preserved. He had a good job, a house in Garland, and a 4-year-old son. He was careful with his prophylaxis. He had not missed a scheduled infusion in eleven months.
His father, Ernesto Delgado-Vega, was a 63-year-old retired truck driver who had driven long-haul routes between Dallas and Laredo for thirty years and had come to live with Marco and his family six months earlier after Ernesto’s wife had died. Ernesto had not been closely involved in Marco’s medical care when Marco was a child — he had driven the routes that paid the bills while Marco’s mother had managed the clinic appointments. Now, retired and present, Ernesto had spent six months watching Marco infuse factor concentrate three mornings per week while seemingly perfectly healthy, and he had questions.
“Mijo, ¿para qué te pones ese medicamento cuando no estás sangrando? Parece un desperdicio. Yo con mis diabetes me tomo la metformina cuando como — tiene sentido. Pero esto… te lo pones tres días a la semana aunque te sientas perfecto.” (Son, why do you inject that medication when you are not bleeding? It seems like a waste. With my diabetes I take the metformin when I eat — that makes sense. But this… you do it three days a week even when you feel perfectly fine.)
Marco was accustomed to this question. He had answered it for co-workers, for in-laws, for the parents of his son’s preschool friends. But he wanted his father to understand it properly — to understand the actual mechanism, not just the conclusion — and he scheduled an appointment with his HTC nurse, Diana Pacheco-Reyes, to have the conversation with both of them present.
Diana had been an HTC nurse at the UT Southwestern hemophilia treatment center for eleven years. She began the explanation where she always began it — with what the coagulation system actually is and what factor VIII does in it.
“Don Ernesto, le voy a explicar cómo funciona el sistema de coagulación, porque para entender por qué Marco se pone el factor tres veces a la semana cuando está sano, hay que entender qué pasa cuando su nivel de factor baja demasiado.” (Don Ernesto, I am going to explain how the coagulation system works, because to understand why Marco infuses factor three times per week when he is healthy, you need to understand what happens when his factor level drops too low.)
She explained the two phases of normal hemostasis. The first phase — primary hemostasis — is the platelet plug: when a blood vessel wall is disrupted, platelets adhere to exposed collagen, activate, and aggregate into a temporary plug that seals the break within seconds. This works for small surface cuts and capillary-level injuries. For deeper injuries, the primary platelet plug is not sufficient. The second phase — secondary hemostasis, the coagulation cascade — reinforces the platelet plug by weaving a net of fibrin protein across and through it, creating a stable, durable clot. Factor VIII is the central accelerator of this fibrin-generating process.
“El factor ocho es como el motor que acelera la producción de fibrina. Sin el factor ocho funcionando, el sistema de coagulación puede producir algo de fibrina por otros caminos — pero muy despacio, muy poco. No lo suficiente para sellar una hemorragia profunda. El resultado es que los sangrados que en una persona normal se detienen solos en minutos — un golpe en una articulación, una contusión en el músculo — en Marco continúan durante horas o días si no tiene el factor.” (Factor VIII is like the engine that accelerates fibrin production. Without factor VIII working, the coagulation system can produce some fibrin through other pathways — but very slowly, very little. Not enough to seal a deep hemorrhage. The result is that bleeds that in a healthy person stop on their own in minutes — a joint hit, a muscle bruise — in Marco continue for hours or days if he does not have the factor.)
Ernesto nodded slowly. He understood machinery. He had driven trucks with failing components and knew what happened when a critical piece stopped working. “Pero ¿por qué lo tiene que poner cuando no hay un golpe? Si no se golpeó, no hay sangrado.” (But why does he have to inject it when there has been no hit? If he did not get hit, there is no bleed.)
This was the second part of the explanation, and the one that most families needed the most time with. Diana leaned forward.
“En la hemofilia severa — con factor ocho por debajo de un uno por ciento del normal — los sangrados articulares no necesitan un golpe. Ocurren espontáneamente. Las articulaciones están cargadas con fuerza durante la actividad normal: caminar, subir escaleras, cargar una caja, torcer el tobillo ligeramente. El tejido sinovial dentro de la articulación tiene muchos vasos sanguíneos pequeños. Cuando el nivel de factor ocho está por debajo del uno por ciento y esos vasos sufren microtraumas durante el movimiento normal, no pueden sellar solos. El sangrado ocurre dentro de la articulación aunque Marco no sienta un golpe, aunque no haya moretón afuera.” (In severe hemophilia — with factor VIII below one percent of normal — joint bleeds do not require a hit. They occur spontaneously. Joints are loaded with force during normal activity: walking, climbing stairs, carrying a box, slightly twisting an ankle. The synovial tissue inside the joint has many small blood vessels. When the factor VIII level is below one percent and those vessels suffer microtrauma during normal movement, they cannot seal themselves. The bleed occurs inside the joint even if Marco does not feel a hit, even if there is no visible bruise outside.)
Ernesto was very still. He looked at Marco. “¿Y eso pasa sin que sientas nada?” (And that happens without you feeling anything?)
“A veces sí siento una sensación extraña — como calor, o un poco de presin. Pero a veces no. El sangrado ya empezó antes de que llegue el dolor.” (Sometimes I do feel something strange — like warmth, or a little pressure. But sometimes no. The bleed has already started before the pain arrives.)
Diana continued to the third part of the explanation — the one that made prophylaxis not just reasonable but essential.
“Lo que hace especialmente importante la profilaxis es lo que le pasa a la articulación después de cada sangrado. Cuando la sangre entra al espacio articular, los glóbulos rojos se rompen y liberan hemoglobina. Esa hemoglobina se descompone en productos que contienen hierro — ferritina, hemosiderina — que se depositan permanentemente en el tejido sinovial. El hierro es tóxico para el cartílago articular. Activa células llamadas sinoviocitos que producen citocinas inflamatorias, y esas citocinas activan osteoclastos — células que destruyen hueso y cartílago. Cada sangrado, aunque sea pequeño y aparentemente se resuelva, deja un depósito de hierro que activa un ciclo de inflamación.” (What makes prophylaxis especially important is what happens to the joint after each bleed. When blood enters the joint space, the red blood cells break down and release hemoglobin. That hemoglobin is broken down into iron-containing products — ferritin, hemosiderin — that are deposited permanently in the synovial tissue. Iron is toxic to articular cartilage. It activates cells called synoviocytes that produce inflammatory cytokines, and those cytokines activate osteoclasts — cells that destroy bone and cartilage. Each bleed, even a small one that appears to resolve, leaves an iron deposit that activates a cycle of inflammation.)
“¿Y ese daño se puede revertir?” (And can that damage be reversed?) Ernesto asked.
“No. El daño articular por la hemofilia es acumulativo e irreversible. Cada sangrado añade un poco más. Con el tiempo, el tejido sinovial se engruesa — lo que llamamos sinovitis hemofílica — y esa membrana sinovial engrosada tiene más vasos sanguíneos y es más susceptible a nuevos sangrados. Así se forma la articulación diana — la articulación que sangra repetidamente porque el daño previo la hace más vulnerable. Los pacientes con hemofilia que no recibieron profilaxis desde pequeños llegan a los cuarenta años con articulaciones que parecen de alguien de setenta. Articulaciones que necesitan reemplazo quirúrgico. Articulaciones que no les permiten trabajar, caminar, vivir con normalidad.” (No. Joint damage from hemophilia is cumulative and irreversible. Each bleed adds a little more. Over time, the synovial tissue thickens — what we call hemophilic synovitis — and that thickened synovial membrane has more blood vessels and is more susceptible to new bleeds. This is how a target joint forms — a joint that bleeds repeatedly because prior damage makes it more vulnerable. Patients with hemophilia who did not receive prophylaxis from a young age reach their forties with joints that look like those of someone in their seventies. Joints that need surgical replacement. Joints that do not allow them to work, walk, or live normally.)
Ernesto was quiet for a long time. He looked at Marco’s left ankle — the one with the target joint, the one that had a visible thickening around the joint line — and then looked away. “¿Eso pasó porque no empezó la profilaxis a tiempo?” (Did that happen because prophylaxis was not started in time?)
“En los años 90, la profilaxis era más nueva — los protocolos no estaban tan establecidos. Marco empezó a los dos años, que es temprano, pero tuvo algunos sangrados antes de que el protocolo estuviera completamente optimizado. Lo que tiene en el tobillo izquierdo y el codo derecho es el resultado de esos sangrados. Lo que tiene el resto de sus articulaciones — que están sanas — es el resultado de treinta y dos años de profilaxis sin interrupciones.” (In the nineties, prophylaxis was newer — the protocols were not as established. Marco started at two years old, which is early, but had some bleeds before the protocol was fully optimized. What he has in the left ankle and right elbow is the result of those bleeds. What the rest of his joints have — which are healthy — is the result of thirty-two years of uninterrupted prophylaxis.)
Ernesto looked at his son. Then at the factor VIII vial on the infusion tray. “Entónces el medicamento no es para cuando estás sangrando.” (So the medication is not for when you are bleeding.)
“La profilaxis no es para tratar los sangrados,” Marco said. “Es para que no haya sangrados.” (Prophylaxis is not for treating bleeds. It is so there are no bleeds.)
Ernesto nodded slowly, the nod of a man who had spent thirty years maintaining trucks and understood that a component serviced before failure was entirely different from a component replaced after breakdown. “Como el mantenimiento preventivo.” (Like preventive maintenance.)
“Exactamente como el mantenimiento preventivo.”
Scenario 2: Lucía Torres-Medina — 9, fourth-grader from San Antonio, Texas
Lucía Torres-Medina had been diagnosed with severe hemophilia A at birth, when prolonged umbilical cord bleeding had prompted a hematology consultation. She was the first in her family with the diagnosis — a de novo F8 pathogenic variant, a large exon deletion producing no functional FVIII protein. Her mother Valentina Torres, a 34-year-old pharmacy technician at an H-E-B pharmacy in San Antonio, had become one of the most meticulous hemophilia parents her HTC team had ever worked with. She had learned to access Lucía’s port, reconstitute recombinant FVIII, and prime the infusion tubing. She kept a bleed diary in a dedicated notebook. She attended every quarterly HTC visit with a printed list of questions.
Lucía had been on prophylactic recombinant factor VIII three times per week since the age of fourteen months. For four years, her bleeds had been minimal — two spontaneous ankle bleeds in her entire life, both managed promptly and without joint sequelae. Her joints were healthy. She played on a soccer team. She was, by every objective measure, a prophylaxis success story.
Three weeks ago, she had woken with a swollen, painful right knee. Valentina had recognized it immediately as a hemarthrosis and called the HTC after-hours line. She was told to administer the standard prophylaxis dose. She administered it. The knee did not respond. She administered a second dose six hours later — the on-call hematologist had approved a double dose, which was the first sign that something was wrong. The knee swelling was increasing rather than improving. An inhibitor screen ordered that morning had returned a result that had changed everything: Bethesda units 48.
Valentina had driven Lucía to the Children’s Hospital of San Antonio that morning and then, on transfer protocol, to the hemophilia treatment center at UT Health San Antonio two hours away. She was sitting in the HTC consultation room with Lucía, whose knee was elevated and wrapped, when HTC nurse Carmen Lozano-Fuentes came to explain what had happened and what was going to happen next.
“Valentina, quiero explicarle qué pasó con el factor ocho de Lucía, porque sé que lo que está viviendo esta semana es muy confuso y alarmante. El medicamento que funcionó perfectamente durante cuatro años dejó de funcionar. Eso necesita una explicación completa.” (Valentina, I want to explain to you what happened with Lucía's factor VIII, because I know that what you are living through this week is very confusing and alarming. The medication that worked perfectly for four years has stopped working. That needs a complete explanation.)
Valentina had her notebook open. She was writing before the nurse had finished the first sentence.
“Lo que Lucía tiene se llama inhibidor del factor ocho. Un inhibidor es un anticuerpo — una proteína producida por el sistema inmunológico — que reconoce el factor ocho como si fuera algo extraño y lo neutraliza. El anticuerpo se une al factor ocho infundido antes de que pueda funcionar en la coagulación.” (What Lucía has is called a factor VIII inhibitor. An inhibitor is an antibody — a protein produced by the immune system — that recognizes factor VIII as if it were something foreign and neutralizes it. The antibody binds to infused factor VIII before it can function in coagulation.)
“¿Por qué ahora? Lleva cuatro años poniendo el mismo medicamento.” (Why now? She has been taking the same medication for four years.)
“Es una pregunta importante. En la hemofilia A severa — especialmente con las mutaciones que no producen ningún factor ocho endógeno, como el tipo de mutación que tiene Lucía — el sistema inmunológico del paciente nunca ha visto el factor ocho. Nunca aprendió a tolerarlo. Cada vez que se infunde factor ocho, el sistema inmunológico lo procesa y puede empezar a producir anticuerpos contra él. Los inhibidores se desarrollan típicamente en los primeros cincuenta días de exposición al factor — pero a veces toman años en aparecer, especialmente en pacientes que no tienen respuesta inicial. El hecho de que hayan pasado cuatro años sin inhibidor no significaba que el riesgo hubiera desaparecido.” (It is an important question. In severe hemophilia A — especially with mutations that produce no endogenous factor VIII, as Lucía's type of mutation — the patient's immune system has never seen factor VIII. It never learned to tolerate it. Each time factor VIII is infused, the immune system processes it and may begin producing antibodies against it. Inhibitors typically develop in the first fifty days of factor exposure — but sometimes take years to appear, especially in patients who do not have an initial response. The fact that four years passed without an inhibitor did not mean the risk had disappeared.)
Valentina looked at Lucía, whose knee was visible above the blanket. “¿Y ahora el factor ocho no sirve de nada?” (And now factor VIII is useless?)
“Con un título de 48 unidades Bethesda, el sistema de Lucía neutraliza el factor ocho que infundimos antes de que llegue a donde se necesita. La unidad Bethesda es una medida de la potencia del inhibidor — cuánto plasma de Lucía se necesita para neutralizar la mitad del factor ocho en una muestra de referencia. Un título de 48 significa que los anticuerpos son muy potentes. Incluso si aumentáramos la dosis al triple o al quádruplo, el factor ocho sería neutralizado antes de poder actuar. Es por eso que el doble de dosis que autorizamos anoche no funcionó.” (With a titer of 48 Bethesda units, Lucía's system neutralizes the factor VIII we infuse before it reaches where it is needed. The Bethesda unit is a measure of the inhibitor's potency — how much of Lucía's plasma is needed to neutralize half the factor VIII in a reference sample. A titer of 48 means the antibodies are very potent. Even if we increased the dose threefold or fourfold, the factor VIII would be neutralized before it could act. That is why the double dose we authorized last night did not work.)
“¿Entonces qué van a darle?” (So what are you going to give her?)
“Vamos a usar un medicamento que se llama FEIBA. El nombre completo es ‘factor eight inhibitor bypassing activity’ — actividad que pasa por alto el inhibidor del factor ocho. Lo que FEIBA hace es completamente diferente al factor ocho.” (We are going to use a medication called FEIBA. The full name is 'factor eight inhibitor bypassing activity' — activity that bypasses the factor VIII inhibitor. What FEIBA does is completely different from factor VIII.)
Carmen drew a simple diagram of the coagulation cascade on the consultation room whiteboard — not all thirteen factors, but the key pathway: the top, where factor VIII normally accelerates factor X activation; the bottom, where thrombin cleaves fibrinogen into fibrin to form the clot. She marked the step where FVIII normally acts with a large X and drew an arrow around it.
“FEIBA contiene factores de coagulación que ya están parcialmente activados — factores IIa, VIIa, IXa, y Xa. Estos factores generan trombina directamente, por debajo del punto donde el factor ocho actuaría normalmente. El inhibidor de Lucía bloquea el factor ocho — pero el factor ocho no está en FEIBA. Los anticuerpos de Lucía no tienen objetivo en FEIBA. El coágulo se forma igualmente, por una ruta diferente.” (FEIBA contains coagulation factors that are already partially activated — factors IIa, VIIa, IXa, and Xa. These factors generate thrombin directly, below the point where factor VIII would normally act. Lucía's inhibitor blocks factor VIII — but factor VIII is not in FEIBA. Lucía's antibodies have no target in FEIBA. The clot forms anyway, through a different route.)
Valentina was writing quickly, the shorthand of someone who processed important information through her notebook. “¿Y por qué no siempre se usa ese medicamento entonces, si funciona aunque haya inhibidor?” (And why not always use that medication then, if it works even with an inhibitor?)
“Porque FEIBA es más difícil de dosificar que el factor ocho — no tenemos una forma tan directa de medir que el nivel de coagulación en el laboratorio está donde queremos que esté. También tiene un riesgo pequeño pero real de trombosis, especialmente con dosis muy altas o administración muy frecuente. Y es mucho más costoso. Para una paciente sin inhibidor, el factor ocho directo es más predecible, más seguro, y más fácil de monitorear. FEIBA se reserva para cuando el factor ocho ya no puede funcionar.” (Because FEIBA is harder to dose than factor VIII — we do not have as direct a way to measure that the coagulation level in the laboratory is where we want it to be. It also has a small but real risk of thrombosis, especially with very high doses or very frequent administration. And it is much more expensive. For a patient without an inhibitor, direct factor VIII is more predictable, safer, and easier to monitor. FEIBA is reserved for when factor VIII can no longer function.)
Lucía had been listening quietly. She was nine years old, and she had understood more than Valentina expected. “Mami, los anticuerpos esperan al factor ocho y lo agarran antes de que llegue. FEIBA llega por otro camino y no los encuentra.” (Mom, the antibodies wait for factor VIII and catch it before it arrives. FEIBA comes through another route and doesn’t meet them.)
Carmen looked at Lucía with the appreciation of an HTC nurse who had spent years explaining this to adults. “Exactamente eso.”
Valentina closed her notebook for a moment. “¿Y el inhibidor va a desaparecer algún día?” (And will the inhibitor ever go away?)
“Hay un tratamiento llamado inducción de tolerancia inmune — inmunoterancia. Consiste en infundir factor ocho en dosis altas todos los días, durante meses o años. El objetivo es ‘cansar’ al sistema inmunológico — hacer que las células que producen los anticuerpos se agoten o aprendan a tolerar el factor ocho. En pacientes que son buenos candidatos, tiene una tasa de éxito del 60 al 70 por ciento. Es un proceso largo y requiere mucho compromiso. Pero para Lucía, que es joven, con buena salud en general y que tiene a usted como mamá — esto es exactamente el tipo de situación para la que está diseñada la inmunoterancia.” (There is a treatment called immune tolerance induction — immunotolerance. It consists of infusing factor VIII in high daily doses for months or years. The goal is to 'exhaust' the immune system — to make the antibody-producing cells wear out or learn to tolerate factor VIII. In patients who are good candidates, it has a success rate of 60 to 70 percent. It is a long process and requires a lot of commitment. But for Lucía, who is young, generally healthy, and has you as her mother — this is exactly the type of situation immune tolerance was designed for.)
Valentina reopened her notebook. “¿Cuándo empezamos?” (When do we start?)
Scenario 3: Carmen Salinas-Rojas — 26, elementary school teacher from Phoenix, Arizona
Carmen Salinas-Rojas had grown up understanding hemophilia from the outside. Her maternal uncle Roberto had severe hemophilia A and had received on-demand treatment during the 1980s before prophylaxis was standard — he now had hemophilic arthropathy in both knees and the right ankle, walked with forearm crutches, and had been on disability for seven years. Her younger brother Miguel had been diagnosed with severe hemophilia A at birth and had been on prophylaxis since infancy, with dramatically better joint outcomes than their uncle. Carmen had watched both trajectories and had understood, from an early age, that she carried something in her X chromosome.
At a preconception appointment with her obstetrician, she had mentioned the family history. The OB had reassured her: “Carriers typically don't have hemophilia symptoms — it’s an X-linked recessive condition, so as long as you have one normal copy, you should be fine. Your sons would have a 50 percent chance of being affected.” Carmen had accepted this. Her fiancé Diego Montoya — a 28-year-old electrician from Mesa — had also accepted it, with the concerned attention of someone who was about to become part of a family that managed a genetic condition.
Her primary care physician had referred her to the Phoenix hemophilia treatment center, and the intake call had included a question Carmen had not expected: “Has anyone measured your own factor VIII level?” The answer was no. She had assumed it was normal. She had not had unusual bleeding, she thought — though she had always had heavy menstrual periods, and she had bled for eight days after her wisdom teeth extraction in college and been told this was “normal for some people.”
Her factor VIII level had come back at 29 percent of normal.
She and Diego were sitting in the consultation room with HTC nurse Roberto Guzmán-Cervantes, a 41-year-old nurse with seventeen years of experience at the Phoenix HTC. Diego had his phone out with a note-taking app. Carmen had been quiet for most of the drive from Mesa — she was processing the idea that she had not, in fact, been “fine.”
“Carmen, el nivel de factor ocho del 29 por ciento que obtuvimos explica varias cosas que probablemente has atribuido a otras causas durante años. Quiero explicarle a Diego y a ti por qué pasa esto en una portadora, porque el concepto de ‘portadora sin síntomas’ es una simplificación que no siempre es correcta.” (Carmen, the 29 percent factor VIII level we obtained explains several things you have probably attributed to other causes for years. I want to explain to Diego and you why this happens in a carrier, because the concept of 'carrier without symptoms' is a simplification that is not always correct.)
He started with the genetics of X-chromosome inactivation, which is where the variability in carrier phenotype comes from.
“La hemofilia A es una enfermedad ligada al cromosoma X. El gen F8, que produce el factor ocho, está en el cromosoma X. Los hombres tienen un X y un Y — si su X tiene una variante patogénica en el gen F8, no tienen ninguna copia funcional del gen y tienen hemofilia severa. Las mujeres tienen dos X — si uno tiene la variante y el otro está normal, tienen una copia funcional. Eso es lo que hace a las portadoras. Hasta aquí, la simplificación es correcta.” (Hemophilia A is an X-chromosome-linked disease. The F8 gene, which produces factor VIII, is on the X chromosome. Men have one X and one Y — if their X has a pathogenic variant in the F8 gene, they have no functional copy of the gene and have severe hemophilia. Women have two X chromosomes — if one has the variant and the other is normal, they have one functional copy. That is what makes carriers. Up to here, the simplification is correct.)
“Pero hay un paso biológico que la simplificación omite: la inactivación del cromosoma X. En los primeros días del desarrollo embrionario — cuando el embrión tiene solo unas pocas docenas de células — cada célula desactiva permanentemente uno de sus dos cromosomas X. Esto se llama lionización, por la bióloga Mary Lyon que lo describió en 1961. La inactivación es al azar: en algunas células se inactiva el X materno, en otras el X paterno. Y una vez que una célula decide cuál X desactivar, todas sus células hijas toman la misma decisión para siempre.” (But there is a biological step that the simplification omits: X-chromosome inactivation. In the first days of embryonic development — when the embryo has only a few dozen cells — each cell permanently deactivates one of its two X chromosomes. This is called lyonization, after biologist Mary Lyon who described it in 1961. The inactivation is random: in some cells the maternal X is inactivated, in others the paternal X. And once a cell decides which X to inactivate, all of its daughter cells make the same decision forever.)
Diego looked up from his phone. “¿Y eso es diferente en cada persona?” (And that is different in each person?)
“Exactamente. La proporción de células que inactivan el X normal versus el X con la variante del gen F8 varía de mujer a mujer. Si la mayoría de las células de una portadora inactivan el X normal — es decir, dejan activo el X con la variante — la mayoría de sus células producen poco o ningún factor ocho. Su nivel de factor ocho será bajo, quizás tan bajo como el 5 o el 10 por ciento. Si, por el contrario, la mayoría de sus células inactivan el X afectado y dejan activo el X normal, su nivel de factor ocho puede estar en el 50 o el 60 por ciento — casi normal. El resultado es que las portadoras obligadas — como Carmen, hija de un padre con hemofilia — pueden tener niveles de factor ocho que van del 5 al 60 por ciento, dependiendo de cómo les salió la distribución del azar embrionario.” (Exactly. The proportion of cells that inactivate the normal X versus the X with the F8 gene variant varies from woman to woman. If most of a carrier's cells inactivate the normal X — meaning they leave active the X with the variant — most of her cells produce little or no factor VIII. Her factor VIII level will be low, perhaps as low as 5 or 10 percent. If, conversely, most of her cells inactivate the affected X and leave the normal X active, her factor VIII level may be at 50 or 60 percent — nearly normal. The result is that obligate carriers — like Carmen, the daughter of a father with hemophilia — can have factor VIII levels ranging from 5 to 60 percent, depending on how the embryonic random distribution turned out for them.)
Carmen had been very still. “¿Y el 29 por ciento significa que la mayoría de mis células están usando el X malo?” (And 29 percent means most of my cells are using the bad X?)
“Sí. Significa que la distribución en tu caso fue relativamente desfavorable. El 29 por ciento está por debajo del umbral de 50 por ciento por debajo del cual las portadoras tienen un fenotipo de sangrado clínicamente significativo. No es hemofilia severa — el nivel de riesgo de sangrado espontáneo en articulaciones que tiene tu hermano o tu tío no es el tuyo. Pero es suficientemente bajo para producir sangrado menstrual abundante, sangrado prolongado después de procedimientos dentales y quirúrgicos, y potencialmente hemorragia posparto.” (Yes. It means that the distribution in your case was relatively unfavorable. 29 percent is below the 50 percent threshold below which carriers have a clinically significant bleeding phenotype. It is not severe hemophilia — the level of spontaneous joint bleeding risk your brother or uncle has is not yours. But it is low enough to produce heavy menstrual bleeding, prolonged bleeding after dental and surgical procedures, and potentially postpartum hemorrhage.)
Diego spoke before Carmen could. “¿Los períodos abundantes que siempre has tenido?” (The heavy periods you have always had?)
“Con un factor ocho del 29 por ciento, la coagulación en el sangrado menstrual es menos eficiente. El sangrado tarda más en detenerse, el flujo es mayor, pueden pasar coágulos. Lo que tu ginecólogo probablemente vio como un patrón menstrual en el extremo pesado del espectro normal puede ser una manifestación de tu nivel de factor. El sangrado de ocho días después de la extracción del molar del juicio también encaja.” (With a factor VIII of 29 percent, coagulation during menstrual bleeding is less efficient. Bleeding takes longer to stop, flow is heavier, clots may pass. What your gynecologist probably saw as a menstrual pattern at the heavy end of the normal spectrum may be a manifestation of your factor level. The eight days of bleeding after the wisdom tooth extraction also fits.)
Carmen let out a quiet breath. Eight days of bleeding she had been told was “normal for some people.”
“Para el embarazo y el parto, esto es especialmente importante,” Diana continued. “Normalmente, el factor ocho sube durante el embarazo — el cuerpo produce más como respuesta a las demás hormonas del embarazo. Pero en portadoras con niveles bajos de base, el aumento puede no ser suficiente. Vamos a monitorear tu nivel de factor ocho durante el embarazo y asegurarnos de que esté por encima de 50 por ciento para el parto. Si no llega, podemos infundirte factor ocho antes de la entrega para reducir el riesgo de hemorragia. El nivel de factor también determina si estás calificada para anestesia epidural — que requiere nivel por encima de 50 por ciento para colocarla de forma segura.” (For pregnancy and delivery, this is especially important. Normally, factor VIII rises during pregnancy — the body produces more in response to the other pregnancy hormones. But in carriers with low baseline levels, the increase may not be sufficient. We will monitor your factor VIII level during pregnancy and make sure it is above 50 percent for delivery. If it does not get there, we can infuse factor VIII before delivery to reduce the risk of hemorrhage. The factor level also determines whether you are eligible for epidural anesthesia — which requires a level above 50 percent for safe placement.)
Diego had been quiet for several minutes, processing. Now he asked the question Carmen had also been forming. “¿Y nuestros hijos?” (And our children?)
“Si Carmen tiene un hijo varón: el 50 por ciento de sus hijos varones heredarán el X afectado de Carmen y tendrán hemofilia A severa. El otro 50 por ciento heredará el X normal y no tendrán la enfermedad. Si Carmen tiene una hija: el 50 por ciento de sus hijas heredarán el X afectado de Carmen y serán portadoras — algunas con niveles de factor normales, otras con niveles bajos como los de Carmen, dependiendo de su propia lionización. El otro 50 por ciento heredará el X normal y no serán portadoras.” (If Carmen has a male child: 50 percent of her sons will inherit the affected X from Carmen and will have severe hemophilia A. The other 50 percent will inherit the normal X and will not have the disease. If Carmen has a daughter: 50 percent of her daughters will inherit the affected X from Carmen and will be carriers — some with normal factor levels, others with low levels like Carmen's, depending on their own lyonization. The other 50 percent will inherit the normal X and will not be carriers.)
“¿Hay alguna forma de saber antes del embarazo?” (Is there any way to know before pregnancy?)
“Sí. Existen dos opciones principales. El diagnóstico genético preimplantacional con fertilización in vitro — se llama DGP o PGT-M en inglés — permite analizar los embriones antes de transferirlos al útero y seleccionar solo los que no tienen la variante del gen F8. Esto evita transmitir la hemofilia desde el principio. Si se produce un embarazo de manera natural, el diagnóstico prenatal por biopsia de vellosidades coriónicas — que se hace entre las diez y las doce semanas — o por amniocentesis — entre las quince y las veinte semanas — puede determinar el sexo del feto y si lleva la variante del gen F8. Cada familia decide cómo quiere proceder con esa información — no hay una respuesta correcta.” (Yes. There are two main options. Preimplantation genetic testing with in vitro fertilization — called PGT-M in English — allows embryos to be analyzed before transfer to the uterus and selects only those without the F8 gene variant. This prevents transmitting hemophilia from the beginning. If pregnancy occurs naturally, prenatal diagnosis by chorionic villus sampling — done between ten and twelve weeks — or amniocentesis — between fifteen and twenty weeks — can determine fetal sex and whether it carries the F8 gene variant. Each family decides how they want to proceed with that information — there is no correct answer.)
Carmen had been quiet for a long time. She was looking at the factor VIII level written in her notes: 29%. Something that had felt like just a number twenty minutes ago was becoming a thread that connected the heavy periods, the wisdom tooth bleeding, the OB’s reassurance, and the future she was planning with Diego. “El 29 por ciento no es ‘portadora asintomática.’” (29 percent is not 'asymptomatic carrier.')
“No. El 29 por ciento es una portadora con fenotipo de sangrado que lleva años sin diagnóstico. Y ahora que lo sabemos, podemos manejarlo.” (No. 29 percent is a carrier with a bleeding phenotype who has been undiagnosed for years. And now that we know, we can manage it.)